Grace Therapeutics Files 8-K

Ticker: GRCE · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1444192

Grace Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyGrace Therapeutics, INC. (GRCE)
Form Type8-K
Filed DateNov 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-reporting, company-update

TL;DR

Grace Therapeutics dropped an 8-K on 11/13/25 - check financials and operations.

AI Summary

Grace Therapeutics, Inc. filed an 8-K on November 13, 2025, reporting on its results of operations, financial condition, and other events. The filing also includes financial statements and exhibits. The company was formerly known as Acasti Pharma Inc. before changing its name on August 28, 2008.

Why It Matters

This 8-K filing provides an update on Grace Therapeutics' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Grace Therapeutics, Inc.?

The primary purpose is to report on the company's results of operations and financial condition, as well as other events, and to include financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on November 13, 2025.

What was Grace Therapeutics, Inc. formerly known as?

Grace Therapeutics, Inc. was formerly known as Acasti Pharma Inc.

On what date did the company change its name from Acasti Pharma Inc.?

The company changed its name on August 28, 2008.

Where is Grace Therapeutics, Inc. headquartered?

Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey.

Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-11-13 08:01:09

Key Financial Figures

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On November 13, 2025, Grace Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing or document.

01

Item 8.01 Other Events. On November 13, 2025, the Company updated its corporate presentation, which includes its updated cash position as of October 31, 2025. A copy of the updated corporate presentation is attached hereto as Exhibit 99.2 to this Form 8-K and is incorporated by reference into this Item 8.01.

01

Item 9.01 Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated November 13, 2025. 99.2 Corporate Presentation, dated November 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. GRACE THERAPEUTICS, INC. Date: November 13, 2025 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing